<DOC>
	<DOCNO>NCT01096082</DOCNO>
	<brief_summary>Design : Phase II-III , double-blind , parallel , placebo control randomized Clinical trial Background : Spinocerebellar ataxia type 3 ( SCA-3 ) autosomal dominant adult-onset neurodegenerative disorder current treatment . Patients invariably become dependent others unable walk disease course . Hypothesis : Lithium Carbonate safe effective treat neurological symptom improve quality life patient SCA3 . Outcomes : Primary - Phase 2 - To assess safety tolerability Lithium Carbonate patient SCA3 6 month follow-up - Phase 3 ( Phase II study show safety therapy ) - To assess efficacy Lithium Carbonate patient SCA3 Neurological Examination Score SCA 3 ( NESSCA ) 12 month follow-up . Secondary 1 . - To assess efficacy neurological function , ataxic , depressive quality life score Lithium Carbonate patient SCA3 Scale Assessment Rating Ataxia ( SARA ) , 9-Hole Peg Board test , 8m walking time , PATA repetition rate , Click Test , SCA Functional Index ( SCAFI ) , Composite Cerebellar Functional Score ( CCFS ) , Beck Depression Inventory , Barthel Index WHOQol 6 12 month follow-up . 2 . - To assess effect Lithium Carbonate peripheral level expression treatment biomarkers ( BDNF , NSE , HDAC , GSK-3Beta ) Study Duration : 12 month - Final analysis phase 2 ( safety study ) 6 month continuous monitor end phase 3 ( efficacy study ) . - Preliminary analysis efficacy ataxia scale 6 month study final analysis phase 3 12 month . Obs : A futility analysis perform 12 month therapy statistically significant difference group find . This analysis define study continue 18 24 month follow-up end 12 month . Location : Hospital de Clínicas de Porto Alegre Subjects : 60 molecularly diagnose SCA3 patient outpatient unit Medical Genetics Service Hospital de Clínicas de Porto Alegre Intervention : Lithium Carbonate tablets 300mg . Starting dose 300mg/day drug titration 49 day achieve defined target lithium serum level 0.5 0.8 mEq/L</brief_summary>
	<brief_title>Safety Efficacy Lithium Carbonate Patients With Spinocerebellar Ataxia Type 3</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Prior molecular diagnose SCA3 determine number CAG expand repeat . Not restrict wheelchair . With disease duration 2 10 year 16 year old . Signs cardiopathy , elevate level creatinine , transaminase , bilirubins 1.5 time normal upper limit baseline . History previous lithium carbonate significant adverse reaction , drug abuse alcoholism . Disturbance thyroid function baseline . Participation another clinical trial le 4 week study entrance . Current use valproic acid , memantine , neuroleptic anticoagulant If individual ( woman ) agree utilize high effective contraceptive method study period 3 month studyend .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>spinocerebellar ataxia</keyword>
	<keyword>Treatment</keyword>
	<keyword>Lithium carbonate</keyword>
</DOC>